High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing

Approximately 85% of patients with Alport syndrome (hereditary nephritis) have been estimated to have mutations in the X chromosomal COL4A5 collagen gene; the remaining cases are autosomal with mutations in the COL4A3 or COL4A4 genes located on chromosome 2. In the present work, the promoter sequenc...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Society of Nephrology Vol. 9; no. 12; pp. 2291 - 2301
Main Authors MARTIN, P, HEISKARI, N, NEUMANN, H, SPRINGATE, J, SHOWS, T, PETTERSSON, E, TRYGGVASON, K, JING ZHOU, LEINONEN, A, TUMELIUS, T, HERTZ, J. M, BARKER, D, GREGORY, M, ATKIN, C, STYRKARSDOTTIR, U
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 01.12.1998
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Approximately 85% of patients with Alport syndrome (hereditary nephritis) have been estimated to have mutations in the X chromosomal COL4A5 collagen gene; the remaining cases are autosomal with mutations in the COL4A3 or COL4A4 genes located on chromosome 2. In the present work, the promoter sequence and previously unknown intron sequences flanking exons 2 and 37 of COL4A5 were determined. Furthermore, intron sequences flanking the other 49 exons were expanded from 35 to 190 to facilitate mutation analysis of the gene. Using this information, all 51 exons and the promoter region were PCR-amplified and sequenced from DNA of 50 randomly chosen patients with suspected Alport syndrome. Mutations were found in 41 patients, giving a mutation detection rate of 82%. Retrospective analysis of clinical data revealed that two of the cases might be autosomal. Although it could not be determined whether the remaining seven cases (14%) were autosomal or X chromosome-linked, it is likely that some of them were autosomal. It is concluded that PCR amplification and direct DNA sequencing of the promoter and exons is currently the best procedure to detect mutations in COL4A5 in Alport syndrome.
ISSN:1046-6673
1533-3450
DOI:10.1681/asn.v9122291